CAR T-Cell Therapy: Insights from Tandem Meetings 2026 | Healio
The field of chimeric antigen receptor (CAR) T-cell therapy continues to evolve rapidly, with recent presentations at the Tandem Meetings | Transplantation &. Cellular Therapy Meetings of ASTCT and CIBMTR highlighting promising advances in next-generation CAR designs and strategies to overcome resistance. These developments, discussed by postdoctoral fellow Maria Caterina Rotiroti, PhD, at Dana-Farber Cancer Institute, offer potential improvements in efficacy and durability of this powerful immunotherapy approach for cancer.
Next-Generation CAR Designs: Engineering for Persistence
A key focus of the preclinical research presented at the meeting centered on engineering CAR T-cells for improved persistence – their ability to remain active and functional within the body for a longer period. Prolonged persistence is often correlated with more durable responses, particularly in solid tumors where CAR T-cell infiltration can be limited. Researchers are exploring various genetic modifications to enhance T-cell survival and function. One approach, presented by Weber E. At the conference, involves genetic engineering to bolster CAR T-cell resilience. Healio reports that these modifications aim to address the challenges of T-cell exhaustion and limited expansion within the tumor microenvironment.
These next-generation CAR designs aren’t simply about boosting the signal; they’re about refining the entire interaction between the T-cell and the cancer cell. This includes optimizing the CAR receptor itself, as well as the signaling domains within the T-cell that control activation, proliferation, and survival. The goal is to create CAR T-cells that are not only potent killers but also capable of establishing long-term immunological memory.
Unraveling Mechanisms of Resistance
Despite the remarkable success of CAR T-cell therapy in certain hematological malignancies, a significant proportion of patients eventually relapse. Understanding the mechanisms underlying this resistance is crucial for developing strategies to improve outcomes. Presentations at the Tandem Meetings addressed several potential resistance mechanisms, including intrinsic factors within the leukemia cells themselves and extrinsic factors related to the tumor microenvironment. Davis K. Presented research on leukemia intrinsic resistance mechanisms, exploring how cancer cells can evade CAR T-cell recognition or suppress T-cell function. Healio also covered Gardener R.’s presentation on clinical predictors and new approaches to overcome resistance.
One identified pathway involves the downregulation of target antigens – the proteins on cancer cells that CAR T-cells recognize. If cancer cells lose or reduce expression of the target antigen, CAR T-cells are unable to bind and kill them. Another mechanism involves the activation of immunosuppressive pathways within the tumor microenvironment, which can dampen T-cell activity and promote immune evasion. Researchers are investigating ways to overcome these resistance mechanisms, such as combining CAR T-cell therapy with other immunomodulatory agents or engineering CAR T-cells to be resistant to immunosuppression.
CAR T-Cell Therapy: A Primer
CAR T-cell therapy is a form of immunotherapy that involves genetically modifying a patient’s own T-cells to recognize and attack cancer cells. T-cells are collected from the patient’s blood and engineered in a laboratory to express a chimeric antigen receptor (CAR) – an artificial receptor that binds to a specific protein on the surface of cancer cells. These modified CAR T-cells are then infused back into the patient, where they seek out and destroy cancer cells expressing the target antigen. Currently, CAR T-cell therapies are approved for the treatment of certain blood cancers, including leukemia and lymphoma, but research is ongoing to expand their use to solid tumors.
Clinical Implications and Future Directions
The advancements presented at the Tandem Meetings suggest that the future of CAR T-cell therapy lies in more sophisticated CAR designs and a deeper understanding of resistance mechanisms. These insights are paving the way for the development of more effective and durable therapies for a wider range of cancers. The ongoing research into genetic engineering approaches to enhance T-cell persistence and overcome immunosuppression holds particular promise. However, it’s important to note that these are still early-stage findings, and further research is needed to translate these preclinical observations into clinical benefits.
Rotiroti’s disclosures indicate a consulting role and equity holdings in Link Cell Therapies, a company involved in CAR T-cell development, which is standard practice in this rapidly evolving field. It’s a reminder that scientific progress is often intertwined with commercial interests, and transparency regarding potential conflicts of interest is essential.
What’s on the Horizon for CAR T-Cell Research?
The field is now focused on several key areas. Clinical trials are underway to evaluate the safety and efficacy of next-generation CAR T-cell therapies in patients with various cancers. Researchers are also exploring the use of CAR T-cell therapy in combination with other cancer treatments, such as chemotherapy, radiation therapy, and immune checkpoint inhibitors. Efforts are being made to reduce the toxicity associated with CAR T-cell therapy, such as cytokine release syndrome (CRS) and neurotoxicity. The ultimate goal is to develop CAR T-cell therapies that are not only effective but also safe and accessible to all patients who could benefit from them. The C-SPAN website confirms activity around medical research on March 11, 2026, though it doesn’t specify details related to CAR T-cell therapy. C-SPAN
The Anna Maria Islander newspaper’s e-edition for March 11, 2026, does not contain information related to CAR T-cell therapy. The Anna Maria Islander